[CAS NO. 1438416-21-7] MJN110

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1438416-21-7]

Catalog

AS940628

Brand

Arctom Scientific

CAS

1438416-21-7

DESCRIPTION [1438416-21-7]

Overview

MDL	MFCD26960823
Molecular Weight	462.33
Molecular Formula	C22H21Cl2N3O4
SMILES	O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)CC1)ON4C(CCC4=O)=O

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

Summary

MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC ₅₀ s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively ^[1] . MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity ^[2] .

IC50 & Target

IC50: 9.1 nM (hMAGL) and 2.1 nM (2-AG) ^[1]

In Vitro

MJN110 (0.01-1000 nM; 4 hours) has the primary serine hydrolase target, hMAGL, with an IC ₅₀ of ~1 nM and 10- and 100-fold selectivity windows over ABHD6 and LYPLA1/2, respectively ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis ^[2]

Cell Line:	Human-derived PC3 cells
Concentration:	0.01, 0.1, 1, 10, 100, 1000 nM
Incubation Time:	4 hours
Result:	HMAGL acted as the primary serine hydrolase target with an IC ₅₀ of ~1 nM.

In Vivo

MJN110 (i.p.; 0.0818 mg/kg; twice daily for 5.5 days) reverses chronic constriction injury (CCI)-induced mechanical allodynia and thermal hyperalgesia in a dose-dependent manner. The respective ED ₅₀ value (95% confidence limits) is 0.430 (0.233-0.793) mg/kg ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6J mice ranged from 18 to 35 g ^[1]
Dosage:	0.0818 mg/kg
Administration:	I.p.; twice daily for 5.5 days
Result:	Reversed CCI-induced mechanical allodynia and thermal hyperalgesia in a dose-dependent manner.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL ( 540.74 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1630 mL	10.8148 mL	21.6296 mL
5 mM	0.4326 mL	2.1630 mL	4.3259 mL
10 mM	0.2163 mL	1.0815 mL	2.1630 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

1-Piperazinecarboxylic acid, 4-[bis(4-chlorophenyl)methyl]-, 2,5-dioxo-1-pyrrolidinyl ester

2,5-Dioxopyrrolidin-1-yl 4-[bis(4-chlorophenyl)methyl]piperazine-1-carboxylate

MJN 110